dr. mcdermott on vegf/pd-1 inhibition in rcc
Published 4 years ago • 88 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:51
dr. mcdermott on vegf plus pd-1 in renal cell carcinoma
-
0:45
dr. mcdermott on the role of vegf targeted therapy in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:45
combined blockade of vegf and pd-1 signaling in rcc
-
0:42
dr. mcdermott on targeting pd-1 and pd-l1 in kidney cancer
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
12:48
myopericytoma...inside a big blood vessel! (intravascular myopericytoma)
-
7:05
vascular endothelial growth factor-a (vegf-a)
-
8:46
today immunotherapy can cure even fourth stage cancer: dr dattatreyudu nori
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:05:38
watch drs. choueiri, mcdermott, and tannir, discuss the latest in rcc: https://bit.ly/3n3x59m
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
35:00
t cell checkpoint inhibitors in rcc: a new hope? david f. mcdermott, m.d.
-
1:37
dr. choueiri on synergy between immunotherapy and vegf inhibitors in rcc
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
4:04
a novel cxcr4 inhibitor for rcc and a novel immunotherapy endpoint | david mcdermott
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc